Inky Cap

Metadata

Regulatory Status

United States

• FDA status: Not approved for any therapeutic use. Not marketed as a dietary supplement. Not GRAS.
• Edibility: Recognized as an edible mushroom when consumed without alcohol, but not commercially cultivated or widely marketed.
• Poison control: The coprine-alcohol interaction is a recognized toxicological syndrome reported to poison control centers.

European Union

• Status: Recognized as an edible wild mushroom in European foraging traditions, with the well-known caveat regarding alcohol avoidance. Not subject to novel food regulation as a traditional food. Not marketed as a dietary supplement or functional food.
• Traditional use: Long history of foraging in Europe, particularly in France, Italy, Germany, and Scandinavia. Traditional knowledge of the alcohol interaction predates its scientific characterization.

United Kingdom

• Status: Known edible wild mushroom. Foraging handbooks consistently warn about the alcohol interaction.

China and East Asia

• Status: The species is distributed in China and East Asia. Not used in traditional Chinese medicine. Not listed in the Chinese Pharmacopoeia.

Conditions & Indications

Primary: No Clinically Validated Therapeutic Indications

• Historical pharmacological interest: Following the isolation and characterization of coprine in 1975, there was brief interest in its potential as an alcohol deterrent (similar to disulfiram/Antabuse). However, animal studies revealed mutagenic and adverse reproductive effects, which terminated this line of development.

Toxicological Significance: Coprine-Alcohol Interaction (Disulfiram-Like Reaction)

• Mechanism: Coprine is hydrolyzed in vivo to 1-aminocyclopropanol, which is rapidly converted to cyclopropanone hydrate. Cyclopropanone hydrate binds covalently to the thiol group in the active site of mitochondrial aldehyde dehydrogenase (ALDH2), irreversibly inhibiting the enzyme. When alcohol (ethanol) is subsequently consumed, normal ethanol metabolism via alcohol dehydrogenase produces acetaldehyde, but acetaldehyde cannot be efficiently converted to acetate due to ALDH2 inhibition. The resulting acetaldehyde accumulation produces the characteristic flush syndrome.
• Temporal window: The coprine-alcohol interaction can occur if alcohol is consumed from 30 minutes to up to 5 days after mushroom ingestion, reflecting the irreversible nature of ALDH2 inhibition (enzyme function recovers only as new enzyme is synthesized).
• Clinical presentation: Facial and neck flushing, nausea, vomiting, malaise, agitation, palpitations, tachycardia, hypotension, tingling in limbs, headache, excessive salivation. Symptoms typically arise 5—10 minutes after alcohol consumption and resolve within 2—3 hours if no further alcohol is consumed.

Preclinical Bioactivities (Limited Evidence)

• Antioxidant activity: Methanolic extract of C. atramentaria demonstrates antioxidant activity in standard in vitro assays, attributed to phenolic compounds (p-hydroxybenzoic acid, coumaric acid, cinnamic acid).
• Antimicrobial activity: Extracts show antifungal and antibacterial activity against selected pathogens in vitro.
• Cytotoxic activity: Organic acids from C. atramentaria (p-hydroxybenzoic, coumaric, cinnamic acid) and their methylated/glucuronate derivatives have demonstrated cytotoxic activity against selected cancer cell lines in vitro. Methylated derivatives showed enhanced cytotoxicity compared to parent compounds.
• Antitumor activity: Polysaccharide extracts have shown antitumor activity in preclinical models. [NEEDS-RESEARCH]
• Nutritional value: Good source of iron, protein, and minerals. Potential role in addressing anemia in populations with limited access to animal protein. [NEEDS-RESEARCH]

Mechanism of Action

Primary Mechanisms

1. Coprine metabolism to 1-aminocyclopropanol: Coprine (N5-(1-hydroxycyclopropyl)-L-glutamine) is a hydrolytic prodrug. After ingestion, coprine is hydrolyzed (likely by glutaminase enzymes) to release 1-aminocyclopropanol, the pharmacologically active metabolite. This hydrolysis occurs rapidly in the gastrointestinal tract and liver.

2. Cyclopropanone hydrate formation and ALDH2 inactivation: 1-Aminocyclopropanol undergoes rapid non-enzymatic conversion to cyclopropanone hydrate (gem-diol of cyclopropanone). Cyclopropanone hydrate is a highly reactive electrophile that forms a covalent adduct with the essential cysteine thiol residue (Cys302 in human ALDH2) in the active site of mitochondrial aldehyde dehydrogenase. This covalent modification is irreversible, permanently inactivating the enzyme molecule. New enzyme must be synthesized to restore ALDH2 activity, which accounts for the prolonged temporal window (up to 5 days) of alcohol sensitivity.

3. Acetaldehyde accumulation and flush syndrome: With ALDH2 inactivated, ethanol metabolism produces acetaldehyde (via alcohol dehydrogenase) that cannot be efficiently converted to acetate. Elevated blood acetaldehyde levels produce vasodilation (flushing), nausea, and sympathetic activation (tachycardia, palpitations) through direct toxic effects and stimulation of catecholamine release.

Pharmacological Comparison with Disulfiram

• Shared mechanism: Both coprine (via 1-aminocyclopropanol) and disulfiram (Antabuse) inhibit ALDH, producing acetaldehyde accumulation when alcohol is consumed.
• Key difference: Disulfiram additionally inhibits dopamine beta-hydroxylase (DBH), which converts dopamine to norepinephrine. This DBH inhibition by disulfiram produces a different cardiovascular response profile to ethanol, with more pronounced hypotension. Coprine does not inhibit DBH. This mechanistic distinction may account for differences in the severity and character of the cardiovascular response between coprine-alcohol and disulfiram-alcohol reactions.
• Irreversibility: Both produce irreversible enzyme inactivation, but coprine’s active metabolite (cyclopropanone hydrate) acts via a different chemical mechanism (electrophilic cysteine modification) than disulfiram’s metabolite (diethyldithiocarbamate chelation).

Secondary Mechanisms

• Phenolic compound antioxidant activity: p-Hydroxybenzoic acid, coumaric acid, and cinnamic acid scavenge reactive oxygen species through standard phenolic antioxidant mechanisms (hydrogen atom transfer, single electron transfer).
• Autodigestion (deliquescence): A distinctive feature of Coprinopsis species is the enzymatic autodigestion (deliquescence) of the fruiting body, producing a black “ink” rich in melanin pigments. This process, mediated by endogenous chitinases and other hydrolytic enzymes, is responsible for the common name “inky cap.” Historically, the black liquid was used as writing ink.

Clinical Evidence Summary

Human Clinical Trials

None. No controlled clinical trials have been conducted with Coprinopsis atramentaria, coprine, or 1-aminocyclopropanol for any indication.

Key Pharmacological and Toxicological Studies

Evidence Limitations

• No therapeutic clinical trials: The coprine-alcohol interaction, while pharmacologically well characterized, has never been evaluated in a controlled clinical trial as a therapeutic intervention.
• Mutagenic/reproductive toxicity terminated development: Animal studies demonstrating mutagenic effects and adverse reproductive outcomes effectively ended any prospect of developing coprine as a therapeutic ALDH inhibitor.
• Limited preclinical bioactivity data: The antioxidant, antimicrobial, and cytotoxic activities described for C. atramentaria extracts are based on a small number of in vitro studies using crude extracts. No systematic investigation of therapeutic potential (excluding the ALDH inhibition) has been conducted.
• Case report-based safety data: Safety information regarding the coprine-alcohol interaction derives primarily from case reports and poison control databases, not from controlled pharmacokinetic studies. The dose-response relationship for coprine and the temporal dynamics of ALDH2 recovery have not been rigorously characterized in humans.
• Variable coprine content: Coprine concentration varies between specimens based on age, growing conditions, and preparation. No standardized quantification method is routinely applied to commercial or wild-harvested specimens.

Safety Profile

General Assessment

Coprinopsis atramentaria is edible when consumed without alcohol and presents no significant toxicity in that context. However, the coprine content makes it functionally dangerous for anyone who consumes alcohol within a 5-day window around mushroom ingestion. The coprine-alcohol reaction, while rarely life-threatening in otherwise healthy adults, can cause significant discomfort and cardiovascular stress that may be dangerous in individuals with pre-existing cardiovascular disease.

Contraindications

• Alcohol consumption: The most critical and absolute contraindication. Alcohol in any form (beverages, cooking wines, alcohol-containing medications, mouthwash) must be avoided from 30 minutes before to at least 5 days after consumption of C. atramentaria. The 5-day window reflects the irreversible nature of ALDH2 inhibition.
• Disulfiram (Antabuse) therapy: Additive ALDH inhibition could produce severe acetaldehyde accumulation even from trace alcohol exposure.
• Metronidazole and other ALDH inhibitors: Concurrent use may produce additive ALDH inhibition.
• Cardiovascular disease: The tachycardia and hypotension of the coprine-alcohol reaction pose risks for patients with coronary artery disease, heart failure, or arrhythmias.
• Pregnancy: Coprine’s mutagenic and reproductive toxic effects in animal models contraindicate use during pregnancy.

Drug Interactions

• Ethanol-containing medications: Many liquid medications, cough syrups, and oral solutions contain ethanol as a solvent. These could trigger a coprine reaction.
• Disulfiram: Additive ALDH inhibition.
• Metronidazole, chlorpropamide, griseofulvin: These drugs also produce disulfiram-like reactions; combined use with coprine could be synergistic.
• Acetaldehyde-generating medications: Any drug that increases acetaldehyde levels could worsen the reaction.

Side Effects

• Without alcohol: Minimal adverse effects when consumed as a young, fresh-cooked mushroom. Rare gastrointestinal discomfort possible.
• With alcohol (coprine reaction):
  • Immediate (5—10 minutes after alcohol): Facial and neck flushing, warmth, erythema
  • Short-term (10—60 minutes): Nausea, vomiting, tachycardia, palpitations, hypotension, headache, malaise, chest discomfort, tingling in extremities
  • Duration: Typically 2—3 hours if no additional alcohol consumed
  • Severe cases (rare): Cardiovascular collapse, arrhythmia (in patients with pre-existing cardiac disease)

Toxicology

• Mutagenicity: Coprine has demonstrated mutagenic activity in standard assays (Ames test and others). This finding was the primary reason therapeutic development as an ALDH inhibitor was abandoned.
• Reproductive toxicity: Animal studies demonstrated adverse reproductive effects, including effects on spermatogenesis.
• No chronic toxicity data from repeated consumption without alcohol exposure. Traditional foragers who consume the species regularly (while abstaining from alcohol) have not reported chronic adverse effects, but systematic long-term safety studies are absent.
• Misidentification risk: C. atramentaria must be distinguished from Coprinopsis picacea (magpie inkcap, gastrointestinal toxin) and from the edible Coprinus comatus (shaggy mane), which does not contain coprine and can be safely consumed with alcohol.

Clinical Dosage

No Established Therapeutic Dose

No clinical dosing recommendations exist because no therapeutic applications have been developed.

Culinary Use (Food — Without Alcohol)

• Fresh fruiting body: Harvested young, before autodigestion begins. Caps should be firm and closed, with gills still white to pale grey. Must be cooked promptly after harvest as autodigestion proceeds rapidly.
• Typical serving: 100—200 g fresh weight, sauteed or added to dishes. Must be consumed the same day as harvest.
• Critical safety instruction: Absolutely no alcohol consumption for at least 3—5 days after eating C. atramentaria. This includes alcohol in cooking wines, sauces, and alcohol-containing medications.

Toxicological Reference (Coprine-Alcohol Interaction)

• Minimum toxic interaction dose: Not precisely established in humans. Even small servings of the mushroom (50—100 g fresh) contain sufficient coprine to produce the ALDH inhibition effect.
• Alcohol threshold: Even small amounts of alcohol (a single drink) can trigger the flush syndrome in a coprine-sensitized individual.
• Duration of sensitivity: Up to 5 days after mushroom consumption, reflecting the time required for de novo synthesis of ALDH2 enzyme to restore normal acetaldehyde metabolism.

Sources

• Hatfield GM, Schaumberg JP. Isolation and structural studies of coprine, the disulfiram-like constituent of Coprinus atramentarius. J Pharm Sci. 1975;64(9):1460-1463
• Lindberg P, Bergman R, Wickberg B. Isolation and structure of coprine, a novel physiologically active cyclopropanone derivative from Coprinus atramentarius and its synthesis via 1-aminocyclopropanol. J Chem Soc Perkin Trans 1. 1977;(6):684-691
• Carlsson A, Henning M, Lindberg P, et al. On the disulfiram-like effect of coprine, the pharmacologically active principle of Coprinus atramentarius. Acta Pharmacol Toxicol (Copenh). 1978;42(4):292-297
• Tottmar O, Lindberg P. Effects on rat liver acetaldehyde dehydrogenases in vitro and in vivo by coprine, the disulfiram-like constituent of Coprinus atramentarius. Acta Pharmacol Toxicol (Copenh). 1977;40(4):476-481
• Michelot D. Poisoning by Coprinus atramentarius. Nat Toxins. 1992;1(2):73-80
• Heleno SA, Ferreira ICFR, Calhelha RC, et al. Cytotoxicity of Coprinopsis atramentaria extract, organic acids and their synthesized methylated and glucuronate derivatives. Food Chem Toxicol. 2014;63:214-220
• Wiseman JS, Abeles RH. Mechanism of inhibition of aldehyde dehydrogenase by cyclopropanone hydrate and the mushroom toxin coprine. Biochemistry. 1979;18(3):427-435
• Benjamin DR. Mushroom poisoning in infants and children: the Amanita pantherina/muscaria group. J Toxicol Clin Toxicol. 1992;30(1):13-22
• Barceloux DG. Medical Toxicology of Natural Substances: Foods, Fungi, Medicinal Herbs, Plants, and Venomous Animals. John Wiley & Sons; 2008

Connections

• Alcohol metabolism and ALDH inhibition: The coprine-ALDH2 inhibition mechanism in C. atramentaria is the most well-characterized disulfiram-like reaction from a natural product. While the pharmaceutical disulfiram (Antabuse) remains in clinical use for alcohol use disorder, coprine’s mutagenic toxicity prevented its development as an alternative. This mechanism has no parallel among other medicinal mushrooms in this reference.
• Comparison with Coprinus comatus (Shaggy Mane): Coprinus comatus is a closely related inky cap species that is edible and does not contain coprine, making it safely consumable with alcohol. C. comatus has its own medicinal properties (hypoglycemic activity, immunomodulation). The critical distinction between these two Coprinus-related species is essential foraging knowledge and underscores the importance of accurate species identification.
• Metabolic enzyme inhibition: Coprine’s mechanism of covalent, irreversible enzyme inhibition represents a pharmacological paradigm (mechanism-based or “suicide” inhibition) that is distinct from the reversible enzyme modulation typically attributed to medicinal mushroom compounds. This places C. atramentaria in a different pharmacological category from mushrooms like Maitake (reversible alpha-glucosidase inhibition for blood sugar management) or Shiitake (eritadenine-mediated cholesterol reduction).
• Toxicological teaching case: The coprine-alcohol interaction is one of the most frequently cited examples in mycotoxicology and pharmacology education, illustrating prodrug metabolism, irreversible enzyme inhibition, and the concept of drug-food interactions. It serves as an important safety teaching point for all foragers.